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2Abstract
Identification of risk factors which are associated with severe clinical signs can assist in the
management of disease outbreaks and indicate future research areas. Pregnancy loss during
late gestation in the mare compromises welfare, reduces fecundity and has financial
implications for horse owners. This retrospective study focussed on the identification of risk
factors associated with pregnancy loss among 46 Thoroughbred mares on a single British
stud farm, with some but not all losses involving equid herpesvirus-1 (EHV-1) infection. In a
sub-group of 30 mares, association between pregnancy loss and the presence of five common
Thoroughbred horse haplotypes of the equine Major Histocompatibility Complex (MHC) was
assessed. This involved development of sequence specific, reverse transcriptase polymerase
chain reactions and in several mares, measurement of cytotoxic T lymphocyte activity. Of the
46 mares, 10 suffered late gestation pregnancy loss or neonatal foal death, five of which were
EHV-1 positive. Maternal factors including age, parity, number of EHV-1 specific
vaccinations and the number of days between final vaccination and foaling or abortion were
not significantly associated with pregnancy loss. In contrast, a statistically significant
association between the presence of the MHC class I B2 allele and pregnancy loss was
identified, regardless of the fetus / foal’s EHV-1 status (p=0.002). In conclusion, this study
demonstrated a significantly positive association between pregnancy loss in Thoroughbred
mares and a specific MHC class I allele in the mother. This association requires independent
validation and further investigation of the mechanism by which the mare’s genetic
background contributes to pregnancy outcome.
3Introduction
Equid herpesvirus-1 (EHV-1) is an alpha herpesvirus which causes respiratory disease and
leads to a cell associated viraemia which, via endothelial cell infection and thrombo-
ischaemia results in late gestation abortion or neonatal foal death (Ma et al., 2013). Despite
routine vaccination of pregnant mares, sporadic EHV-1 abortion outbreaks can still occur.
Host risk factors for the development of herpes viral abortion, including the role of the mare’s
Major Histocompatibility Complex (MHC) class I genotype have received little attention to
date. Classical equine MHC class I genes, also known as the Equine Leukocyte Antigen
(ELA) complex, encode a large number of polymorphic alleles (Tallmadge et al., 2005).
These allelic polymorphisms determine the range of peptides presented to cytotoxic T
lymphocytes (CTL). Fifteen MHC class I serological ELA haplotypes have been identified at
the ELA-A locus, but only a small number of haplotypes are common in the Thoroughbred
breed, namely ELA-A2, ELA-A3, ELA-A5, ELA-A9 and ELA-A10 (Antczak, 1992). The
sharing of MHC class I alleles between individuals can also be demonstrated functionally in
vitro using an EHV-1 specific, cytotoxic T lymphocyte assay (Allen et al., 1995). One EHV-1
CTL target is the immediate early protein (ICP4, encoded by gene 64), which is restricted by
the B2 allele expressed on the ELA-A3 haplotype (Kydd et al., 2006) and an unknown allele
on ELA-A2 (Kydd et al., 2014). Recently, the B2 allele (Eqca-1*00101 using the current
nomenclature) has been shown to bind a single 9 residue peptide, namely RDGARFGEL
within the immediate early protein (Bergmann et al., 2015). The frequency of the B2 allele is
relatively common with estimates ranging from 13.4% to 25% in Thoroughbred horses
(Bergmann et al., 2015; Antczak, D.F 1986).
The study described here exploited a field outbreak of multiple abortions in a herd of
Thoroughbred mares to explore associations between several risk factors and pregnancy
losses, some but not all of which were confirmed as EHV-1 positive. These preliminary
4results suggested a significant association between pregnancy loss and the mare’s MHC class
I allele, regardless of the EHV-1 status of the feto-placental unit. No other significant
associations were identified and vaccination provided partial protection.
Materials and methods
Groups of horses
Three separate groups of horses were used, namely the Cornell (n=9), Newmarket (n=40) and
commercial pregnant Thoroughbred (n=46) herds. The Cornell horses were used to produce
template cDNA for RT-PCR based tests to identify five known ELA haplotypes in the
Thoroughbred horse. This herd consisted of 10 horses of known MHC class I haplotypes,
previously characterised by serological typing and test matings. Nine homozygous horses
included three carrying ELA-A2, three with ELA-A3, one ELA-A5 and one ELA-A9
Thoroughbreds and one ELA-A10 Standardbred horse. The heterozygote carried the ELA-A2
and ELA-A5 haplotypes. These horses were used for the optimisation of the allele-specific
RT-PCRs using a panel of primer pairs. The second group (unrelated to the first) comprised
40 Newmarket Thoroughbreds of unknown haplotype that included a mixed family of half-
and full-siblings, with eight foals by the same sire and six dams. Samples from these animals
were used to validate the RT-PCR in an uncharacterised population. All horses were
maintained according to national and institutional care guidelines, all samples were excess to
requirements when horses were sampled for other reasons and standard ethical approval
procedures were completed. The third group comprised 46 pregnant Thoroughbred mares
which were used for commercial breeding purposes in which an EHV-1 outbreak occurred
(details below).
5RT-PCRs for MHC class I genotyping
Using cDNA extracted from peripheral blood mononuclear cells, RT-PCRs were developed
(Supplementary File 1) to detect selected, sequenced alleles specific for five known ELA
haplotypes in the Thoroughbred horse. To design allele-specific primers, sequence data of all
the equine MHC class I genes (classical and non-classical) previously identified from the
haplotypes ELA-A2, -A3, -A5, -A9, and –A10 were obtained from GenBank® and aligned
using ClustalW2 (www.ebi.ac.uk/Tools/clustalw2/index.html). Five MHC class I alleles, one
per haplotype, were selected based on differences in sequence in the hypervariable regions
(8-9 (A2 haplotype), B2 (A3.1), 5b (A5), 9c (A9) and 10a (A10; Supplementary File 2).
These common haplotypes represent approximately 90% of animals in the Thoroughbred
breed (D.F. Antczak, personal communication). The genes from which the alleles originated
had previously been assigned to four MHC class I loci (Supplementary File 3; see (Tallmadge
et al., 2010) for nomenclature). To capture any additional alleles, generic RT-PCR primers
were also used (adapted from (Chung et al., 2003)) that closely matched homologous regions
of all the classical MHC class I genes but did not bind to known non-classical and
pseudogene sequences. A sample of each RT-PCR amplicon was electrophoresed and
visualized according to standard protocols. Following amplification, all RT-PCR products
were cloned and sequenced using standard methods.
Commercial Thoroughbred broodmares, pregnancy losses and inclusion criteria
Pregnant Thoroughbred mares (n=46) were maintained on a well-managed stud farm in
England and had been vaccinated against EHV-1 and EHV-4 as recommended with an
inactivated, whole virus vaccine with carbomer adjuvant (Equip EHV-1,4, Zoetis UK Ltd.,
London). These mares shared a common paternal or maternal sire at the fourth or fifth
generation. The herd also included five mares which were half-sisters out of two dams.
6Following confirmation of two consecutive EHV-1 positive abortions, 46 mares were
followed to determine their pregnancy outcome. Pregnancy losses which occurred at >100
days of gestation and <1 day post partum were included in the analysis. Potential risk factors
including age, parity, number of EHV-1 specific vaccinations and the number of days
between final vaccination and foaling or abortion were also assessed in 46 mares. Of these 46
mares, excess samples were available from 30 and these were studied retrospectively to
determine any association between their MHC class I genotype and pregnancy loss (EHV-1
positive or any pregnancy loss). Fetuses or neonatal foals and placentae underwent full post
mortem examinations and routine diagnostic tests by accredited pathologists. Twenty five
foaling mares were typed by RT-PCR alone. Of 10 mares with pregnancy loss, two were
typed by RT-PCR and cytotoxic T lymphocyte (CTL; see below) assay, two by RT-PCR
alone, two by CTL assay alone, but samples were unavailable for RT-PCR or CTL from four
mares.
Detection of cytotoxic T lymphocyte (CTL) activity
To confirm and extend RT-PCR results, CTL assays were performed using lymphocytes from
selected Thoroughbred mares to determine the presence of a shared MHC class I allele (Allen
et al., 1995). An MHC class I B2+ pony which was hyper-immune to EHV-1 by previous
experimental infection with strain Ab4, was used as: a) a source of effector cells with high
frequencies of memory CTL activity (positive control) and b) a donor of B2+ target cells.
Other target cells included: a) autologous cells either infected with EHV-1 or medium or a
recombinant vaccinia virus encoding EHV-1 gene 64 (NYVACC g64; Paillot et al., 2006), a
known CTL target protein. Gene 64 encodes the immediate early (IE) protein of EHV-1, a
CTL target when presented by products of the B2 allele (ELA-A3) and potentially, the ELA-
A2 haplotype (Kydd et al., 2014; Kydd et al., 2006). Thus effector CTLs’ lysis of targets
7which present an IE peptide on the B2 allele or an allele on the A2 haplotype can confirm and
extend RT-PCR results; b) B2+ EHV-1 infected target cells were used to demonstrate sharing
of the B2 allele; c) EHV-1 infected targets from four allogeneic Thoroughbred stud farm
mares with pregnancy loss, to determine any shared alleles. Insufficient Thoroughbred
effector cells were available to test target cells for genetic restriction. A positive result was
defined as infected target cells with a percent specific lysis greater than two standard
deviations above that of the mock infected target cells.
Statistical analysis
Pregnancy loss was defined as any abortion or neonatal foal death during the study period
following the initial EHV-1 positive abortion, regardless of the presence or absence of EHV-
1. The risk factor variables were assessed statistically for the strength of their association
with pregnancy loss. For the continuous measures of age of mare in years, number of
previous foals and total number of vaccinations against EHV-1/4, the non-parametric
Wilcoxon rank sum test was used on data from 46 mares. For the binary variable of
presence/absence of the MHC class 1 B2 allele, Fisher’s exact test was applied to data from
30 mares in which the mares’ genotype and pregnancy outcome had been determined.
Statistical analyses were conducted using Stata12.0 statistical software (StataCorp, College
Station, Texas) with statistical significance taken at P≤0.05.  
Results
Characterisation of the MHC class I allele-specific RT-PCR
For each pair of primers, RT-PCR products of the predicted size were obtained from
lymphocyte cDNA originating from the Cornell horses (Supplementary File 4). Each product
8was present only in the specific predicted haplotype and there was no evidence that the allele-
specific primers amplified any products from other haplotypes. Each RT-PCR product was
sequenced and this matched the published database sequences, thus confirming the
amplification of the allele of interest.
The five allele-specific primer pairs were then used to test cDNA samples from 40
Newmarket Thoroughbreds of unknown MHC haplotypes. Each sample produced an RT-
PCR product of the expected size from at least one set of the allele-specific primers. A total
of 28 cDNA samples generated an RT-PCR product from 2 sets of gene-specific primer pairs
indicating a heterozygous genotype. The remaining 12 cDNA samples generated a RT-PCR
product from just one allele-specific primer pair. This latter result may be interpreted as: i)
that two copies of a single allele are present, demonstrating homozygosity or ii) that other
alleles are present which are not recognised by any of the primer pairs, suggesting a
heterozygous genotype. The 40 Newmarket Thoroughbreds included six mares which had
eight offspring between them, sired by the same stallion (Table 1). In three cases (offspring 1,
2 and 4), it is certain that the sire transmitted ELA-A3. In two cases (offspring 6 and 8) the
sire transmitted either ELA-A5 or ELA-A9 and in one case (offspring 3) either ELA-A5 or an
unknown haplotype. The data show that the sire carried ELA-A3 and suggests that the sire’s
other MHC haplotype was ELA-A5. This fits the segregation pattern for all eight offspring
and supports the conclusion that offspring 3, 5, and 7 are true MHC homozygotes. Dams PM
and TJ are possible homozygotes.
To confirm homozygosity in the 12 putative homozygous Newmarket Thoroughbred
samples, a generic RT-PCR (primers in Supplementary File 3) was performed on cDNA, to
allow amplification and sequence analysis of as many of the classical MHC class I genes as
possible from the A2, A3, A5, A9 and A10 haplotypes. Generic RT-PCR products were
cloned from all 12 putative homozygotes. At least 25 clones from each sample were
9sequenced across the binding site and the data compared with published nucleotide and
deduced amino acid sequences of equine MHC class I genes. Sequences were considered a
match to a published gene if they had <five deduced amino acid changes and those with one
to five amino acid changes were classified as an allelic variant rather than a new gene (S.A.
Ellis, Personal Communication). Of the 12 putative homozygous Newmarket Thoroughbred
samples, 10 (including dams PM and TJ and foals 3, 5 and 7) did not result in the
amplification of any additional nucleotide sequences showing homology with other published
Thoroughbred horse-associated MHC class I alleles. These data provide further evidence of
the specificity of the original allele specific RT-PCR and the unique presence of each selected
allele within a single haplotype. In the remaining two putatively homozygous horses
(1*00101, alias B2 (ELA-A3) and N*00101, alias 8-9 (ELA-A2)), the generic classical MHC
class I primers did amplify cDNA of a single additional gene that was homologous to a
published MHC class I gene, 118 expressed on the W11 haplotype (Genbank Accession
number AY176106). MHC class I haplotype information was not available for the sire or
dam of these horses. However, these results indicate that these two horses may be
heterozygous with 1*00101 / 118 (ELA-A3 / W11) and N*00101 / 118 (ELA-A2 / W11)
genes respectively (118 allele frequency 5%; 2/40).
Outbreak of pregnancy loss in Thoroughbred mares and associated risk factor analysis
Following two EHV-1 positive pregnancy losses, the outcome of pregnancy was monitored
over one season in a total of 46 Thoroughbred mares and risk factors for pregnancy loss
investigated. The management included keeping mares in small isolated groups at pasture,
but all were stabled together in a large American barn, with shared airspace, for one night
during particularly bad weather. Thirty six mares produced a viable foal but 10 pregnancy
losses (22%) were recorded and 10 fetuses underwent post mortem diagnostic tests, although
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these were limited in one carcass (#29) due to predation of fetal tissues. Five of the 10
pregnancy losses were attributed to EHV-1 infection (Table 3). All but one of the losses were
at >five months of gestation, including one mare (13) whose neonatal foal died at five hours
post partum. One abortion (mare 38) occurred at 115 days (3.8 months) of gestation. There
were no significant associations between pregnancy loss and the mares’ age, parity, number
of vaccinations or days since last vaccination (Supplementary File 5). The data confirmed
previous field observations that even in vaccinated mares, EHV-1 infection can lead to
pregnancy loss.
Cell mediated immune responses in Thoroughbred mares involved in the outbreak
MHC class I restricted, EHV-1 specific CTL activity was monitored once in PBMC from
5/10 mares with EHV-1 positive pregnancy loss (Table 3; Supplementary File 6). Three of
these mares (13, 20 and 36) had not been MHC class I genotyped by RT-PCR. Maximum
lysis of mock infected target cells was <9.9%. Effector CTL from all five mares showed
positive lysis against autologous EHV-1 infected target cells, suggesting that virus specific,
CTL memory cells were present. Sufficient cells were available for further tests from four of
these five mares. Insufficient effectors were available from mares 5, 13 and 14 to include
allogeneic, infected target cells and thus show genetic restriction. The absence of this control
means that the data from this assay must be interpreted with caution. Effectors from three
mares (5, 13 & 14) showed positive lysis of target cells from a known B2+ horse, implying a
shared expression of the B2 allele. Effectors from these three mares, where sufficient cells
were available, lysed EHV-1 infected target cells from each other, again suggesting the
sharing of MHC class I antigens. Three of these mares lysed NYVACC gene 64 infected
target cells (mares 5, 13 and 14), indicating that target peptides of the immediate early protein
are presented to CTL in these animals (Kydd et al., 2006). These data confirmed and
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extended RT-PCR results, suggesting the presence of a functional B2 allele in mares 5, 13
and 14. Effector CTL from Mare 36 also showed positive lysis against NYVACC gene 64
infected target cells, but there were insufficient effectors to screen on B2+ target cells. As
peptides of the immediate early protein encoded by gene 64 may also be presented by an
allele on the ELA-A2 haplotype (Kydd et al., 2014), no definitive conclusion about mare 36’s
haplotype could be drawn so she was excluded in further analyses.
Application of the MHC class I allele specific RT-PCR to commercial Thoroughbred
broodmares
The presence of alleles 8-9 (A2 haplotype), B2 (A3.1), 5b (A5), 9c (A9) and 10a (A10) was
detected by RT-PCR in 29 mares (25 foaling and four pregnancy losses) and only by CTL
assay in 1 mare (13). One or two RT-PCR products were detected in each of the mares, of
which eight appeared homozygous and 21 heterozygous (Table 2). The five half-sisters
shared either allele 9b or 10c. A total of 30 genotyped mares were therefore included in the
analysis. Of 25 mares that were genotyped and foaled normally, five mares (20%; mares 9,
32, 34, 35 and 39) had the B2 allele. Of these five mares, four were heterozygous (80%) and
one was putatively homozygous. In contrast, in four of the 10 mares which lost their
pregnancy and were RT-PCR typed, the B2 allele was detected in all four mares (100%;
mares 5, 14, 29 and 38; Table 3). Of these four B2+ mares, two showed putatively
homozygous (B2) and two heterozygous (B2/8-9 and B2/9c) genotypes.
To summarise the MHC class I alleles which were determined by RT-PCR and CTL assay in
30 mares, the percent allele frequency was calculated and the distribution according to
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pregnancy outcome illustrated (Figure 1). To reduce bias in putatively homozygous animals,
the allele detected was counted once and “x” was assigned to the potential unknown allele.
The total of 16.7% B2+ (Eqca-1*00101) horses in the current study is comparable with the
13.4% reported by Bergmann et al., (2015).
Statistical analysis of pregnancy outcome and MHC class I genotype
No statistically significant associations were found between pregnancy loss and mares’ age,
total number of previous foals and total number of vaccine doses. The relationship between
the dam’s MHC class I genotype and pregnancy outcome was analysed statistically in 30
mares (excluding mare 36). This demonstrated that of five pregnancies lost in which the
MHC class I allele was determined conclusively, all five (100%) mares contained the B2
allele and three of these mares had an EHV-1 positive abortion. In contrast, of the 25 mares
which foaled successfully, only five (20%) animals carried the B2 allele (four heterozygous
and one putatively homozygous). Statistical analysis by Fisher’s exact test comparing these
proportions demonstrated a statistically significant association (p=0.002) between the
presence of the B2 allele and prevalence of pregnancy loss, where these criteria were known.
Discussion
This study described the characterisation of allele specific primer pairs in an RT-PCR to
differentiate five common MHC class I haplotypes in the Thoroughbred horse. Application of
the method to a population of Thoroughbred broodmares, combined with cross-reactive CTL
activity, revealed a significant association between the presence of the MHC class I B2 allele
and pregnancy loss, regardless of the EHV-1 status of the fetus. This polarisation of clinical
outcome highlights MHC class I as a potential risk factor associated with pregnancy loss in
the Thoroughbred horse.
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Risk factors associated with pregnancy loss are likely to be multifactorial, although only one
was confirmed as statistically significant in the current study, namely the presence of the
MHC class I B2 allele in the dam. This association was also significant in EHV-1 positive
losses. In vitro, MHC class I interacts with EHV-1 at several points in the pathogen’s life
cycle. Thus MHC class I acts as an entry receptor via viral glycoprotein D (Kurtz et al., 2010;
Sasaki et al 2011a). Importantly, it appears that not all MHC class I alleles can act as entry
receptors for EHV-1, but those with an alanine at position 173 in the 2 domain can aid viral
entry (Sasaki et al., 2011b). The B2 allele does have alanine at this position, in common with
all known alleles at the two polymorphic loci (1 and 16; Tallmadge et al., 2010). However in
vitro, although cells transfected with genes from the five common MHC class I haplotypes
were susceptible to EHV-1 infection, amongst cells transfected with seven genes on the ELA-
A3 haplotype, only cells transfected with the B2 (3.1) allele permitted entry of EHV-1 (Azab
et al., 2014). Bergmann et al (2015) have reported a single 9mer peptide binding motif in
EHV-1’s immediate early protein with affinity for the binding groove encoded by Eqca-
1*00101 (B2 allele). The same publication also noted interferon ELIspot responses to this
peptide in PBMC from a single, multiply infected horse which contained the Eqca-1*00101
(B2) allele but not in horses vaccinated with an inactivated virus product. Additional
interactions between EHV-1 and MHC class I have been identified. These include specific
EHV-1 proteins which mediate partial downregulation of MHC class I molecules on the cell
surface via dynamin-dependent endocytosis (Huang et al., 2015) and block the formation of
peptide-MHC class I complexes in the transport associated pathway involved in antigen
presentation (Koppers-Lalic et al., 2008). Bodo et al., (1994) has reported an association
between the ELA-A10 haplotype and higher EHV-1 specific, virus neutralising antibody
titres in peripheral blood, compared with other haplotypes. Thus all these observations point
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to the importance of the host’s individual MHC class I type and its emerging role in the
pathogenesis and immune response to this virus.
Associations between MHC class I alleles and severity of clinical disease have been reported
in people and animals (Blackwell et al., 2009; Dukkipati et al., 2006). For example, the
development of post herpetic neuralgia following varicella zoster virus infection of Japanese
people is associated with a higher frequency of three MHC alleles (Sato-Takeda et al., 2004).
In contrast, a low prevalence of herpes simplex virus-1 infection and disease is associated
with a high frequency of the Human Leukocyte Antigen (HLA-)-B*44 allele (Samandary et
al., 2014). In veterinary species, MHC class I genes have been associated with susceptibility
to disease, including mastitis in cattle (Park et al., 2004). In the horse, there is an association
between MHC class I ELA-A9 haplotype and the development of uveitis (Deeg et al., 2004).
The current data therefore add to the association between MHC class I and disease.
The association between a maternal B2 allele and all pregnancy losses, regardless of EHV-1
status was unexpected. Thus the B2 allele was also detected in two mares which suffered
pregnancy loss and were diagnosed as EHV-1 negative using fetal and placental samples. A
potential explanation is that regardless of the EHV-1 infection status, the B2 allele in the
mare is associated with an inadequate or different innate or adaptive immune response,
leading to the loss of a viable feto-placental unit. For example, antimicrobial peptides in the
human reproductive tract show a high degree of genetic variation and immune-modulatory
function (Yarbrough et al., 2015), which may influence the innate immune response to
pathogens and ultimately the outcome of pregnancy.
Intriguingly, the MHC class I B2 allele was detected in some mares which foaled
successfully. Closer interrogation of the data showed that four out of five of these mares were
heterozygous for the B2 allele. Thus it appears that heterozygosity of the mother may have an
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overriding positive influence on successful pregnancy outcome. Maternal heterozygosity may
dampen any immuno-dominant effect normally associated with the B2 allele or, as discussed
earlier, limit viral invasion and the subsequent immune response. Alternatively, it is possible
that the allele inherited by the feto-placental unit from heterozygous mothers may have
influenced pregnancy outcome, for example compromising the maternal tolerance to paternal
antigens. The influence of individual alleles, such as B2 on this tolerance remains to be
investigated. In women, the placental unit has the capacity to modulate local maternal
immune responses (Racicot et al., 2014). Thus inheritance of the B2 allele may alter the
immunological equilibrium at the feto-maternal interface and / or make it more vulnerable to
challenge by pathogens.
The significant association between pregnancy loss and the MHC class I B2 allele may be
indicative of linkage with another unidentified locus or interaction with another risk factor. In
women, genome wide association studies suggest that unexplained miscarriage may be
associated with dysregulation of expressed genes involved in mitochondrial function and
cytokine production (Lyu et al., 2013; Medica et al., 2009). In cattle, seven genes
representing diverse pathways were moderately associated with fertility and early pregnancy
loss (Minten et al., 2013). Thus using the equine genome sequence (Wade et al., 2009) as a
basis for future genome wide association screening of horses, any genes and biological
pathways involved in pregnancy loss may be elucidated.
In conclusion, this study provides new but preliminary evidence of an apparent positive
association between the loss of an equine pregnancy and the presence of the MHC class I B2
allele in the mother. This newly identified association requires confirmation in other
populations with more complete data sets, but nevertheless highlights an avenue meriting
further research.
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Table 1. Inheritance patterns of predicted MHC class I haplotypes in a mixed half- and full-sibling Thoroughbred horse family. These1
animals were part of 40 Newmarket Thoroughbred horses of unknown MHC class I haplotypes on which the performance of the MHC class2
I, allele specific RT-PCR was tested.3
4
Dam
#
Dam Haplotype(s) Offspring
#
Offspring Haplotype(s) Transmitted Sire
Haplotype
AS ELA-A2 / ELA-A5 1 ELA-A3 / ELA-A5 ELA-A3
AS ELA-A2 / ELA-A5 2 ELA-A3 / ELA-A5 ELA-A3
AS ELA-A2 / ELA-A5 3 ELA-A5 ELA-5 or
Unknown
PM ELA-A2 4 ELA-A2 / ELA-A3 ELA-A3
TJ ELA-A3 5 ELA-A3 ELA-A3 or
Unknown
YO ELA-A5 / ELA-A9 6 ELA-A5 / ELA-A9 ELA-A5 or
ELA-A9
SH ELA-A3 / ELA-A9 7 ELA-A3 ELA-A3 or
Unknown
MO ELA-A5 / ELA-A9 8 ELA-A5 / ELA-A9 ELA-A5 or
ELA-A9
5
6
18
Table 2. Details of the Thoroughbred mares’ involved in the disease outbreak, their pregnancy7
outcomes and MHC class I genotype as determined by RT-PCR (n=29) or CTL assay (mares 13 and8
36). The assumption was made that each allele was expressed on a single ELA-A haplotype. The9
haplotype was then deduced from the presence of DNA for that allele: A2 haplotype – allele 8-9, A3.110
haplotype – allele B2, A5 haplotype – allele 5c; A9 haplotype – allele 9c; A10 haplotype- allele 10a.11
Where only one RT-PCR product was amplified, the animal was likely to have been a homozygote, but12
to reduce bias, was assigned an x allele (X haplotype). * Genotypes of mares 13 and 36 were13
determined by CTL assay as B2 (A3 haplotype) and an unknown allele on the A2 haplotype or B214
respectively. Abbreviations: n/a= sample was not available for RT-PCR typing; no.= number;15
Pregnancy outcomes: F= viable foal; EHV Ab = EHV-1 positive pregnancy loss; Ab = EHV-116
negative pregnancy loss.17
18
Mare no. Pregnancy outcome MHC class I allele(s)detected
Predicted ELA-A haplotype
1 F 9c / x A9 / x
3 F 8-9 / 10a A2 / A10
4 F 8-9 / 10a A2 / A10
5 EHV Ab B2 / x A3 / x
6 F 8-9 / 9c A2 / A9
7 F 8-9 / 5c A2 / A5
9 F B2 / 9c A3 / A9
11 F 8-9 / 10a A2 / A10
12 F 8-9 / x A2 / x
13* EHV Ab B2/ x* A3* / x
14 EHV Ab 8-9 / B2 A2 / A3
19 F 5c / x A5 / x
21 F 8-9 / 9c A2 / A9
23 F 9c / 10a A9 / A10
24 F 8-9 / 5c A2 / A5
25 F 9c / 10a A9 / A10
26 F 5c / 9c A5 / A9
19
28 F 5c / 10a A5 / A10
29 Ab B2 / 9c A3 / A9
31 F 5c / x A5 / x
32 F B2 / 9c A3 / A9
33 F 8-9 / 5c A2 / A5
34 F B2 / x A3 / x
35 F B2 / 9c A3 / A9
36* EHV Ab B2 or x* A2 or A3*
38 Ab B2 / x A3 / x
39 F 8-9 / B2 A2 / A3
40 F 9c / 10a A9 / A10
41 F 5c / x A5 / x
42 F 5c / 9c A5 / A9
44 F 8-9 / 5c A2 / A5
19
20
Table 3. Details of the mares with pregnancy loss and determination of their MHC class I alleles. EHV-1 was detected in fetal and / or20
placental tissues using co-cultivation on Rabbit Kidney 13 indicator cells and amplification of DNA encoding glycoprotein B using specific21
primers. The MHC class I RT-PCR amplified the alleles 8-9 (A2 haplotype), B2 (A3.1) and 9c (A9). The Cytotoxic T Lymphocyte (CTL)22
column summarises the predicted MHC class I allele, as suggested by the ability of that mare’s effector CTL to lyse defined target cells. nd=23
not done. *insufficient material due to predation of carcass.24
25
Mare no. Detection of EHV-1 in fetal Post mortem diagnosis of MHC class I allele detected by26
and / or placental tissues the reason for pregnancy loss the method shown27
28
Virus isolation PCR RT-PCR CTL29
30
5 - + EHV-1 B2 B231
13 + + EHV-1 nd B232
14 + + EHV-1 8-9 / B2 B233
20 - + EHV-1 nd nd34
36 + + EHV-1 nd B235
27 - - Undetermined nd nd36
29 nd - nd* B2 / 9c nd37
30 - - Placentitis nd nd38
37 - - Undetermined nd nd39
38 - - Early placental separation B2 nd40
21
Supplementary File 1.
a) First strand synthesis of RNA. All incubations were performed in a thermocycler with heated lid.
*Moloney Murine Leukaemia Virus Reverse Transcriptase
Step Detail
---------------------------------------------------------------------------------------------------------------------
Elution of RNA from column 50l nuclease free water
RNA storage 65oC 10mins then cool on ice
First strand synthesis 25l Master Mix 10l 5x MMLV RT* buffer
3.2l 2mM dNTPs
1.25l (50units) recombinant RNAse inhibitor (RNase Out)
1l (0.5ug) oligo(dT)12-18
40u MMLV RT
Nuclease free water to 25l
Add master mix to the RNA Incubate 37oC for 1.5hours
b) Details of the generic and allele specific MHC class I RT-PCRs.
a) Reaction mix for allele specific RT-PCR. Total reaction volume was 20l
Step Detail
-------------------------------------------------------------------------------------------------------------------
Template cDNA 1.5l
Amplitaq Gold DNA polymerase1 1 unit
PCR buffer II 1x
MgCl2 2mM
22
Primers 0.5M
dNTPs 200M
dimethyl sulphoxide 2.5%
b) Reaction mix for generic RT-PCR. Total reaction volume was 50l
Step Detail
------------------------------------------------------------------------------------------------------
Template cDNA 3l
Expand High Fidelity enzyme mix2 1.7 units
Expand high fidelity PCR buffer 2 1x
Primers 0.5M
dNTPs 200M
dimethyl sulphoxide 2.5%
c) Cycling conditions for allele specific RT-PCR
Step Temperature (oC) Time (mins)
------------------------------------------------------------------------------------------------------
Denaturation 95oC 5
Cycles (n=35)
1 (denaturation) 95oC 0.5
2 (annealing) 58oC 0.5
3 (elongation) 72oC 0.5
Final elongation 72oC 1
d) Cycling conditions for generic RT-PCR
Step Temperature (oC) Time (mins)
------------------------------------------------------------------------------------------------------
Denaturation 95oC 5
Cycles (n=35)
1 (denaturation) 95oC 0.5
23
2 (annealing) 60oC 0.5
3 (elongation) 72oC 1
Final elongation 72oC 1
1 AmpliTaq Gold DNA polymerase, Applied Biosystems Warrington, Cheshire
2 Taq polymerase and DNA polymerase with proofreading activity for high yield and fidelity, Expand High
Fidelity Enzyme mix Roche, Welwyn Garden City, Hertfordshire.
24
Supplementary File 2. Alignment of DNA sequences (5’ to 3’) of selected regions for the five MHC class I alleles to show regions of
forward and reverse primer binding. Underlined regions are primer sequences for the gene-specific PCR. Boxed regions show
primer sequences for the generic PCR. Primers are 8-9 (gene N*00101; A2 haplotype), B2 (1*00101; A3), 5b (16*00201; A5), 9c
(1*00201; A9) and 10a (N*00501; A10).
5’ ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
10 20 30 40 50 60 70 80 90 100
8-9 ATGCGGATCG TGATGCCCCC AACCTTCCTC CTGCTGCTCT CGGGGGCCCT GAGCCTGACC GAGACCCTGG CTGGCTCCCA CTCCATGAGG TATTTCTACA
3.1(B2) ATGTGCGTCA TGATGCCGCC AACCTTCCTC CTGCTGCTGT CGGGGGCCCT GACCCTGACC GAGACCTGGG CGGGCTCCCA CTCCATGAGA TATTACAAAA
5b ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
9c ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
10a ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
110 120 130 140 150 160 170 180 190 200
8-9 CCGGCGTGTC CCGGCCCGGC CGCGGGGAGC CCCGCTTCGT CGCCGTCGGC TACGTGGACG ACACGCAGTT CGCGCGGTTC GACAGCGACG CCGCGAGTCC
3.1(B2) CCGCCGTGTC CCGGCCCGGC CGCGGGGAGC CCCGCTTCAT CTCCGTCGGC TACGTGGACG ACACGCAGTT CGTGCGGTTC GACAGCGACG CCGCGAGTCC
5b ---------- ---------- ---------- ---------- ---------- ---------- ---------- -GCGCGGTTC GACAGCGACG CCGCGAGTCC
9c ---------- ---------- ---------- ---------- ---------- ---------- ---------- -GTGCGGTTC GACAGCGACG CCGAGAATCC
10a ---------- ---------- ---------- ---------- ---------- ---------- ---------- -GTGCGGTTC GACAGCGACG CCGCGGGTCC
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
210 220 230 240 250 260 270 280 290 300
8-9 GAGGATGGAG CCGCGGGCGC CGTGGATGAA GCAGGAGAGG CCGGAGTATT GGGAGCGGAA CACGCGGATC TTCAAGGACA CAGCACAGAC TTTCCGAGTG
3.1(B2) GAGGATGGAG CCGCGGGCGC GGTGGGTGGA GCAGGAGGGG CCGCAGTATT GGGAAGAAGA GACGCGGACC GCCAAGGGCC ACGCACAGAC TTTCCGAGGG
5b GAAGGAGGAG CCGCTGGCGC CGTGGATGGA GCAGGAGGGG CCGGAGTATT GGGAGGAGAA CACGCGGATC TACAAGGGCA ACGCACAGAC TTTCCGAGAG
9c AAAGGAGGAA CCGCGGGCGC CGTGGATGGA GCAGGAGGGG CCGGAGTATT GGGAAGAGAA CACGCGGCGC GCCAAGGGCC ACGCACAGAC TTCCCGAGTG
10a GAGGATGGAG CCGCGGGCGC CGTGGGTGGA GCAGGAGGGG CCGGAGTATT GGGAAGAAGA GATGCGGACC GCCAAGGGCC ACGCACAGAC TTTCCGAGTG
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
310 320 330 340 350 360 370 380 390 400
8-9 AGCCTGAACA ACCTGCGCGG CTACTACAAC CAGAGCGAGG CCGGGTCTCA CACCCTCCAG GACATGTATG GCTGCGACGT GGGGCCGGAC GGGCGTCTCC
3.1(B2) AACCTGCGGA TCGCGCTCGG CTACTACAAC CAGAGCGAGG CCGGGTCTCA CACCTTCCAG TGGATGTCTG GCTGCGACGT GGGGCCGGAC GGGCGCCTCC
25
5b AACCTGAACA CCCTGCGCGG CTACTACAAC CAGAGCGAGG CCGGGTCTCA CACCCTCCAG TTGATGTACG GCTGCGACGT GGGGCCACAC GGGCGCCTCC
9c AACCTGAACA CCCTGCGCGG CTACTACAAC CAGAGCGAGT CCGGGTCTCA CACCTACCAG GAAATGTATG GCTGCGACGT GGGGTCGGAC AGGCGCCTCC
10a AACCTGAACA CCCTGCGCGG CTACTACAAC CAGAGCGAGG CCGGGTCTCA CACCCTCCAG GAAATGTATG GCTGCGACGT GGGGTCGGAC AGGCGCCTCC
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
410 420 430 440 450 460 470 480 490 500
8-9 TCCGTCGGGT ACAGACAGT- CGCCTACGAC GGCGCCGATT ACATCGCCCT GAACGAGGAC CTGCGCTCCT GGACCGCGGC GGACACGGCG GCTCAGATCA
3.1(B2) TCCG-CGGGT ACAGTCAGTT CGCCTACGAC GGCGCCGATT ACATCGCCCT GAACGAGGAC CTGCGCTCCT GGACCGCGGC GGACACGGCG GCGCAGATCA
5b TCAG-CGCAT CCTTTCAATA CGCCTACGAC GGCGCCGATT ACATCGCCCT GAACGAGGAC CGGCGCTCCT GGACCGCGGC GGACACGGCG GCTCAGATCT
9c TCCG-CGGGT ACATTCAGTT CGCCTACGAC GGCGCCGATT ACATCGCCCT GAACGAGGAC CTGCGCTCCT GGACCGCGGC GGACGCGGCG GCGCAGATCA
10a TCCG-CGGGT ATGAACAGTT CGCCTACGAC GGCGCCGATT ACCTCGCCCT GAACGAGGAC CTGCGCTCCT GGACCGCGGC GGACACGGCG GCTCAGATCA
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
510 520 530 540 550 560 570 580 590 600
8-9 CCCGGCGCAA GTGGGAGGCG GCCGGTGTGG CGGAGGACTT CAGGAACTAC CTGGAGGGCA CGTGCGTGGA GTCGCTCCTC AGATTCCTGG AGAACGGGAA
3.1(B2) CCCGGCGCAA GTGGGAGGCG GCCGGTGAGG CGGAGCAGCA CAGGAACTAC CTGGAGGGCC GGTGCGTGGA GTGGCTCCTC AGATACCTGG AGAACGGGAA
5b CCCGGCGCAA GTTGGAGGCG GCTGGTGTGG CGGAGGGCTA CAGGAACTAC CTGGAGGGGG AGTGCGTGGA GTGGCTCCTC AGATACCTGG AGAACGGGAA
9c CCCGGCGCAA GTTGGAGGCG GCCGGTGTGG CGGAGCAGCG CAGGAACTAC CTGGAGGGGG AGTGCGTGGA GTGGCTCCTC AGACACCTGG AGAACGGGAA
10a CCCGGCGCAA GTGGGAGACG GCCGGTGAGG CGGAGGGCTA CAGGAACTAC CTGGAGGGCA CGTGCGTGGA GTGGCTCCTC AGATACCTGG AGAACGGGAA
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
610 620 630 640 650 660 670 680 690 700
8-9 GGAGACGCTG CAGCGCGCGG ACTCGCCAAA GACACACGTG ACCCACCACC CCATCTCTGA CCGTGAGGTC ACCCTGAGGT GCTGGGCCCT GGGCTTCTAC
3.1(B2) GGAGACGCTG CAGCGCGTGG ACCCTCCGAA GACACATGTG ACCCACCACC CCAGCTCTGA CCATGAGGTC ACCCTGAGGT GCTGGGCCCT GGGCTTCTAC
5b GGAGACGCTG CAGCGCGTGG ATCCCCCAGA GACACACGTG ACCCACCACC CCATCTCTGA CCGTGAGGTC ACCCTGAGGT GCTGGGCCCT GGGCTTCTAC
9c GGAGACGCTG CAGCGCGCGG ACCCCCCGAA GACACATGTG ACCCACCACC CCATCTCTGA CCGTGAGGTC ACCCTGAGGT GCTGGGCCCT GGGCTTCTAC
10a CGAGACACTG CAGCGCGCGG ACGCCCCAAA GACACATGTG ACCCACCACC CCATCTCTGA CCATGAGGTC ACCCTGAGGT GCTGGGCCCT GGGCTTCTAC
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
710 720 730 740 750 760 770 780 790 800
8-9 CCTCCAGAGA TCAGCCTGTC CTGGCAGCGT GATGGGGAGG ACCTGACCCA GGACACGGAG TTTGTGGAGA CCAGGCCTGC AGGGGACGGG ACCTTCCAGA
26
3.1(B2) CCTGCGGAGA TCACCCTGAC CTGGCAGCGT GATGGAGAGG ACCTGACCCA GGACACGGAG TTTGTGGCGA CCAGGCCTGC AGGGGACGGG ACCTTCCAGA
5b CCTGCGGAGA TCGCCCTAAC CTGGCAGCGT GATGGGGAGG ACATGACCCA GGACACGGAG CTTGTGGAGA CCAGGCCTGC AGGGGACGGG ACCTTCCAGA
9c CCTGCGGAGA TCACCCTGAC CTGGCAGCGT GACGGGGAGG ACCTGACCCA GGACACGGAG TTTGTGGCGA CCAGGCCTGC AGGGGACGGG ACCTTCCAGA
10a CCTGAGGAGA TCAGCCTGTC CTGGCAGCGT GACGGGGAGG ACGTGACCCA GGACACAGAG CTTGTGGAGA CCAGGCCTGC AGGGGACCGA ACCTTCCAGA
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
810 820 830 840 850 860 870 880 890 900
8-9 AGTGGGCTGC TGTGGTGGTG CCTTCTGGAG AGGAACAGAG CTACACGTGC CATGTGCAGC ACGAGGGGCT GCCTGAGCCT GTGACCCTGA GATGGGAGCC
3.1(B2) AGTGGGCGGC TGTGGTGGTG CCTTCTGGGG AGGAGCAGAG ATACACGTGC CATGTGCAGC ACGAGGGGCT GCCTGAGCCT GTCACCCGGA GATGGGAGCT
5b AGTGGGCGGC TGTGGTGGTG CCTTCTGGAG AGGAGCAGAG ATACACGTGC CATGTGCAGC ACGAGGGGCT GCCTGAGCCT GTCACCCGGA GATGGGAGCC
9c AGTGGGCGGC TGTGGTGGTG CCTTCTGGGG AGGAGCAGAG ATACACGTGC CATGTGCAGC ACGAGGGGCT GCCTGAGCCC GTCACCCGGA GATGGGAGCC
10a AGTGGGCGGC TGTGGTGGTG CCTTCTGGAG AGGAGCAGAG ATACACGTGC CATGTGCAGC ACGAGGGGCT GCCTGAGCCC CTCACCCTGA GATGGGAGCC
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
910 920 930 940 950 960 970 980 990 1000
8-9 GCCTCCTATG TCCACCATCC TCATCGTGGG CGTCCTTGCT GGCCTGGTTC TCCTTGTCGC TGTGGTGGCT GGAGCTGTGA TCTGGAGGAA GAAGCACTCA
3.1(B2) GCCTCCTCAG TCCACCATCC TCATCGTGAG CATCATTGCT GGCCTGGTTC TCCTTGGAGC TGTGGTGGCT GGAGCTGTGA TCTGGAGGAA GAAGCGCTCA
5b TCCTCCTCAG TCCACCATCC TCATCGTGGG CGTCCTTGCT GGCCTGCTTC TCCTTGTCGC TGTGGTGGCT GGAGCTGTGA TCTGGAGGAA GAAGCACTCA
9c GCCTCCTCAG TCCATCATCC TCATCGTGGG CGTCCTTGCT GGCCTGGTTC TCCTTGGAGC TGTGGTGGCT GGAGCTGTGA TTTGGAGGAA GAAGCGCTCA
10a GCCTCCTCAG TCCACCATCC TCATCGTGGG CGTCCTTGCT GGCCTGGGTC TCCTTGGAGC TGTGGTGGCT GGAGCTGTGA TCTGGAGGAA GAAGCGCTCA
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....| 3’
1010 1020 1030 1040 1050 1060 1070 1080 1090
8-9 GGTGAAAAAA GAGGGATTTA CGTGCAGGCT GCAAACAATG ACAGTGCCCA GGGATCTGAT GCGTCTCTCC CGCAGAAAGT GTGAGACGGT GGCCC
3.1(B2) GGTGAAAAAA GAGGGATTTA CGTGCAGGCT GCAAACAGTG ACAGTGCCCA AGGCTCTGAT GCGTCTCTCC CACAGAAAGT GTGAGACAGT GGCCC
5b GGTGAAAAAA GAGGGATTTA CGTGCAGGCT GCAAACAGTG ACAGTGCCCA AGGCTCTGAT GCGTCTCTCA CTCAGAAAGT GTGAGACAGT GGCCC
9c GGTGAAAAAA GAGGGATTTA CGTGCAGGCT GCAAACAGTG ACAGTGCCCA AGGCTCTGAT GCGTCTCTCC CACAGAAAGT GTGAGACAGT GGCCC
10a GGTGCAAAAA GAGGGATTTA CGTGCAGGCT GCAAACAGTG ACAGTGCCCA GGGATCTGAT GCGTCTCTCC CACAGAAAGT GTGAGACGGT GGCCC
27
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Supplementary File 3. Equine MHC class I genes and primers used to amplify specific alleles by RT-PCR.
Equine
MHC
Haplotype
Locus# Gene
Name#
(Aliases)
GenBank
Accession#
Primer
name
Position
relative to
origin
Primer sequences Predicted
size
(base
pairs)
A2 N N*00101
(8-9)
M95409 8-9F4
8-9R
406-425
707-727
TCCGTCGGGTACAGACAGTC
CAGGACAGGCTGATCTCTGG
322
A3 1 1*00101
(3.1, B2)
DQ083407 B2Fext
B2Rext
68-90
518-536
CCCACTCCATGAGATATTACAAA
TTCCTGTGCTGCTCCGCCT
469
A5 16 16*00201
(5b)
DQ145594 5bF1
5bR
26-44
571-590
GTCCGAAGGAGGAGCCGCT
AGCTCCGTGTCCTGGGTCAT
565
A9 1 1*00201
(9.1, 9c)
DQ145597 9cF
9cR
20-40
387-405
CCGAGAATCCAAAGGAGGAAC
GAGCCACTCCACGCACTCC
386
A10 18 N*00501
(10a)
DQ145599 10aF5
10aR2
601-618
833-856
AGGCCTGCAGGGGACCGA
CTGCACGTAAATCCCTCTTTTTG
256
Generic
ELA^
N/A N/A N/A Classical F
Classical R
exon 3
exon 7/8
CGAGGCCGGGTCTCACACC
GGGCCACTGTCTCACACTTTCTG
~760
#Loci, gene names, and GenBank Accession numbers from Tallmadge et al. (2010). ^primers adapted from Chung et al.
(2003)
N/A = not applicable
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Supplementary File 4. PCR products amplified from the Cornell horses’ lymphocyte cDNA by allele-specific primers associated with the five
selected Thoroughbred MHC class I haplotypes. The haplotypes of horses from which the cDNA was derived are shown at the top of each
lane and a 1kb ladder is also illustrated. a) – d) Allele-specific primers used, their associated serological haplotype and predicted PCR
product size: a) primers 8-9, A2 haplotype; b) primers B2, A3.1 haplotype; c) primers 5b, A5 haplotype and d) left side of gel, primers 9c, A9
haplotype and right side of gel, primers 10a, A10 haplotype.
30
Supplementary File 5. Details of the mares’ ages, reproductive and EHV-1 specific
vaccination histories and pregnancy outcomes. Abbreviations: no.= number; Pregnancy
outcomes: F= viable foal; EHV Ab = EHV-1 positive pregnancy loss; Ab = EHV-1
negative pregnancy loss.
Mare no. Age (years) No. ofprevious foals
Total no. of
vaccine doses Pregnancy outcome
1 9 5 22 F
2 13 8 30 F
3 6 1 15 F
4 19 12 35 F
5 9 4 23 EHV Ab
6 14 7 31 F
7 7 2 18 F
8 9 4 21 F
9 16 10 30 F
10 10 4 22 F
11 17 9 28 F
12 8 4 21 F
13 11 5 24 EHV Ab
14 6 1 14 EHV Ab
15 10 5 24 F
16 7 2 13 F
17 11 6 27 F
18 11 6 27 F
19 22 14 26 F
20 8 3 22 EHV Ab
21 5 0 5 F
22 13 7 28
31
23 7 2 18 F
24 11 4 22 F
25 11 5 24 F
26 12 6 27 F
27 15 7 27 Ab
28 7 2 18 F
29 8 3 20 Ab
30 19 7 26 Ab
31 13 7 27 F
32 20 14 27 F
33 10 4 16 F
34 8 3 17 F
35 9 4 22 F
36 7 2 12 EHV Ab
37 10 4 22 Ab
38 5 0 4 Ab
39 6 1 17 F
40 10 5 23 F
41 11 5 26 F
42 9 3 20 F
43 8 2 12 F
44 17 10 28 F
45 13 7 28 F
46 13 7 29 F
32
Supplementary File 6. Cytotoxic T lymphocyte activity in EHV-1 stimulated, Thoroughbred PBMC
against the target cells shown. Effectors were stimulated with EHV-1 strain Ab4: a) EHV-1
hyperimmune pony mare expressing the MHC class I B2 allele was used as the positive assay control.
b) to e) four Thoroughbred mares sampled once at 5-10 months after EHV-1 positive pregnancy loss.
Target cells are shown on the x axis and are designated as either B2 allele positive or the number of the
mare, followed by target cells’ status: inf = infected with EHV-1; m = mock infected; g64 = NYVACC
gene 64 infected (Kydd et al., 2006; Paillot et al., 2006). Effector to target cell ratios 100:1, 50:1 and
25:1 as shown in a). Bars indicate standard error of mean of three replicate wells.
33
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